Compare POAS & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POAS | XAIR |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.3M |
| IPO Year | 2024 | 2015 |
| Metric | POAS | XAIR |
|---|---|---|
| Price | $0.16 | $3.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 160.2K | 116.0K |
| Earning Date | 05-21-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,679,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 107.26 |
| 52 Week Low | $0.15 | $0.33 |
| 52 Week High | $7.40 | $8.19 |
| Indicator | POAS | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 40.18 |
| Support Level | $0.15 | $0.59 |
| Resistance Level | $0.39 | $7.30 |
| Average True Range (ATR) | 0.01 | 0.61 |
| MACD | 0.01 | -0.32 |
| Stochastic Oscillator | 61.00 | 2.92 |
Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.